Eli Lilly made 11 biotech acquisitions in H1 2026, dominating the industry's M&A total while targeting vaccines, CAR-T, ADCs & sleep disorders.
July 9, 2026 10:00 AM EDT
Lilly was already pharma's biggest company. Now it's doing deals to match
Riding on its trillion-dollar heft and successes in treating obesity, Eli Lilly has now become a force in one area where it …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical…
Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious…
The company's stock has zoomed this year, driven by the explosive growth of the weight-loss drug market.
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune…
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and…
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
